$1.41-0.13|(-8.44%)
52W H: 3.5452W L: 0.76Beta: 2.07

About Equillium Inc

Frequently Asked Questions

What is the 52-week range for EQ?

The 52-week high is $3.54 and the 52-week low is $0.76.

What is the P/E ratio for EQ?

The P/E ratio data is currently unavailable.

What is the dividend yield for EQ?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is -61.43%.

What is the Net Profit Margin?

The Net Profit Margin (TTM) is -19.63%.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 3.30.

Analyst Recommendation Trends

Wall Street analyst consensus for EQ over the last few months:

2026-09-01
Buy: 9
S.Buy: 8
Hold: 1
Sell: 0
2026-08-01
Buy: 9
S.Buy: 8
Hold: 1
Sell: 0
2026-07-01
Buy: 7
S.Buy: 8
Hold: 1
Sell: 0
2026-06-01
Buy: 7
S.Buy: 7
Hold: 2
Sell: 0

Latest EQ News

Equillium Announces Poster Presentations at the 7th International AHR Conference

New preclinical data further characterize EQ504’s effects on epithelial barrier repair and immune regulationLA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in two posters at the 7th International AHR Conference, taking place September 29 to October 2, 2026, in Porto, Portug

Yahoo9/29/2026

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

Equillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined the company’s plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, during a fireside chat. Connelly said t

Yahoo9/27/2026

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. A

Yahoo9/16/2026

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Roth Capital analyst Adam Walsh reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $12 price target.

Benzinga9/4/2026

Related Stocks (Peers)

Companies operating in similar sectors to EQ:

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-06-05Zedelmayer Christine-14,584--
2026-06-05Zedelmayer Christine-14,584$2.9304$42,737
2026-06-05Zedelmayer Christine+14,584$0.785$11,448
2026-06-05Connelly Stephen-30,975$2.9401$91,070
2026-06-04Connelly Stephen-200,000$3.1638$632,760
2026-05-28Tom Penny-65,000--
2026-05-28Tom Penny-65,000$2.95$191,750
2026-05-28Tom Penny+65,000$0.785$51,025
2026-05-28Zedelmayer Christine-15,625--
2026-05-28Zedelmayer Christine-14,583--
2026-05-28Zedelmayer Christine-48,512--
2026-05-28Zedelmayer Christine-7,292--
2026-05-28Zedelmayer Christine-30,208$2.98$90,020
2026-05-28Zedelmayer Christine+15,625$0.785$12,266
2026-05-28Zedelmayer Christine+14,583$0.785$11,448
2026-05-28Zedelmayer Christine-200$2.71$542
2026-05-28Zedelmayer Christine-55,604$2.7$150,131
2026-05-28Zedelmayer Christine+48,512$0.77$37,354
2026-05-28Zedelmayer Christine+7,292$0.73$5,323
2026-05-28McDermott Charles Douglas+70,000--
2026-05-28Troupin Barbara+70,000--
2026-05-28Pruzanski Mark+70,000--
2026-05-28BRADBURY DANIEL+70,000--
2026-05-28DEMSKI MARTHA J+70,000--
2026-05-27Zedelmayer Christine-9,821--
2026-05-27Zedelmayer Christine-9,821$2.7$26,517
2026-05-27Zedelmayer Christine+9,821$0.77$7,562
2026-03-13Zedelmayer Christine-120,312--
2026-03-13Zedelmayer Christine-120,312$2.5003$300,816
2026-03-13Zedelmayer Christine+120,312$0.785$94,445
2026-03-09Zedelmayer Christine-75,000--
2026-03-09Zedelmayer Christine-41,666--
2026-03-09Zedelmayer Christine-35,695--
2026-03-09Zedelmayer Christine-181,219$2$362,438
2026-03-09Zedelmayer Christine+75,000$0.785$58,875
2026-03-09Zedelmayer Christine+41,666$0.785$32,708
2026-03-09Zedelmayer Christine+35,695$0.785$28,021
2026-02-19Zedelmayer Christine-76,562$1.7406$133,264
2026-02-19Zedelmayer Christine+76,562$0.73$55,890
2026-02-19Zedelmayer Christine-109,375$1.7814$194,841
2026-02-19Zedelmayer Christine+109,375$0.785$85,859
2026-02-19Zedelmayer Christine-76,562--
2026-02-19Zedelmayer Christine-109,375--
2026-02-19Zedelmayer Christine-76,562$1.7406$133,264
2026-02-19Zedelmayer Christine+76,562$0.73$55,890
2026-02-19Zedelmayer Christine-109,375$1.7814$194,841
2026-02-19Zedelmayer Christine+109,375$0.785$85,859
2026-01-08Tom Penny-6,533$1.29$8,428
2026-01-07Tom Penny+450,000--
2026-01-07Zedelmayer Christine+500,000--
2026-01-07Connelly Stephen+1,150,000--
2026-01-07Steel Bruce D.+1,750,000--
2025-12-23Zedelmayer Christine-100,000--
2025-12-23Zedelmayer Christine-100,000$1.5$150,000
2025-12-23Zedelmayer Christine+100,000$0.785$78,500
2025-12-15Zedelmayer Christine-11,900$1.31$15,589
2025-12-12Zedelmayer Christine-23,804$1.34$31,897
2025-11-25Zedelmayer Christine-7,998$0.95$7,598
2025-11-25Zedelmayer Christine-100$0.98$98